# US 2021/0196799 A1 · Compositions for Use in the Treatment of Neurological Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196799 A1
- Document ID: US20210196799A1
- Status: Published application
- Kind: A1
- Application number: 16/080,911
- Filed: 2017-02-28
- Published: 2021-07-01
- Earliest claimed: 2016-02-29
- Applicants: University of Ulster
- Inventors: Paula MCCLEAN
- Web page: https://patentgrep.com/patent/US20210196799A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of neurological disorders. Also disclosed are methods of treatment of of neurological disease, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating neurological disorders.

## Claims

### Claim 1

A peptide analogue of xenin for use in the treatment of neurological disorders.

### Claim 2 (depends on 1)

A peptide analogue for use according to claim 1, wherein the peptide analogue comprises xenin and at least one amino acid substitution or modification.

### Claim 3 (depends on 2)

A peptide analogue for use according to claim 2, wherein the at least one amino acid modification comprises addition of a fatty acid selected from the group comprising a C-8 octanoyl group, a C-10 decanoyl group, a C-12 lauroyl group, a C-14 myristoyl group, a C-16 palmitoyl group, a C-18 stearoyl group, and a C-20 acyl group.

### Claim 4 (depends on 2, 3)

A peptide analogue for use according to claim 2 or 3, wherein the at least one amino acid modification comprises the addition of a C-16 palmitoyl group.

### Claim 5 (depends on 3, 4)

A peptide analogue for use according to claim 3 or 4, wherein the or each fatty acid is attached at a lysine residue.

### Claim 6 (depends on 3, 4, 5)

A peptide analogue for use according to any one of claims 3-5, wherein the peptide analogue comprises xenin and a C-16 palmitoyl group attached at the lysine residue at position 13 of the peptide analogue.

### Claim 7

A peptide analogue of gastric inhibitory polypeptide, or a fragment thereof, for use in the treatment of neurological disorders.

### Claim 8 (depends on 7)

A peptide analogue for use according to claim 7, wherein the peptide analogue comprises gastric inhibitory polypeptide and at least one amino acid substitution or modification.

### Claim 9 (depends on 8)

A peptide analogue for use according to claim 8, wherein the at least one amino acid modification comprises acylation of an amino acid residue.

### Claim 10 (depends on 8, 9)

A peptide analogue for use according to claim 8 or 9, wherein the at least one amino acid modification comprises acetylation of the N-terminal amino acid residue of the peptide analogue.

### Claim 11 (depends on 7, 8, 9, 10)

A peptide analogue for use according to any of claims 7-10, wherein the peptide analogue further comprises at least one amino acid modification comprising addition of a fatty acid selected from the group comprising a C-8 octanoyl group, a C-10 decanoyl group, a C-12 lauroyl group, a C-14 myristoyl group, a C-16 palmitoyl group, a C-18 stearoyl group, and a C-20 acyl group.

### Claim 12 (depends on 11)

A peptide analogue for use according to claim 11, wherein the at least one amino acid modification comprises the addition of a C-16 palmitoyl group.

### Claim 13 (depends on 11, 12)

A peptide analogue for use according to claim 11 or 12, wherein the or each fatty acid is attached to a lysine residue.

### Claim 14 (depends on 11, 12, 13)

A peptide analogue for use according to any one of claims 11-13, wherein the or each fatty acid is attached to an alpha or epsilon amino group of a lysine residue.

### Claim 15 (depends on 13, 14)

A peptide analogue for use according to claim 13 or 14, wherein the peptide analogue comprises a C-16 palmitoyl group attached to the lysine residue at position 37 of the peptide analogue.

### Claim 16

A peptide analogue for use according to any preceding claim, wherein the peptide analogue further comprises at least one amino acid modification comprising attachment of a polymer moiety of the general formula HO—(CH2-O—CH2)n-H, wherein n is an integer between 1 and 22.

### Claim 17

A composition for use in the treatment of neurological disorders, wherein the composition comprises a peptide analogue of xenin or a peptide analogue of gastric inhibitory polypeptide, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A peptide analogue for use according to any one of claims 1-16, or a composition for use according to claim 17, wherein use comprises administration of a pharmaceutically effective amount of the peptide analogue or the composition.

### Claim 19 (depends on 18)

A peptide analogue or a composition for use according to claim 18, wherein use comprises administration of 0.25-25.00 nmol/kg body weight of the peptide analogue or an equivalent amount of the composition.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A peptide analogue for use according to any one of claims 1-16, 18, and 19 or a composition for use according to any one of claims 17-19, wherein the neurological disorder is a disorder selected from the group of disorders affecting cognitive function; and dysfunctional cognitive processes.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A peptide analogue for use according to any one of claims 1-16, 18, and 19 or a composition for use according to any one of claims 17-19, wherein the neurological disorder is a neurodegenerative disease.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A peptide analogue for use according to any one of claims 1-16, 18, and 19 or a composition for use according to any one of claims 17-19, wherein the neurological disorder is Alzheimer's disease (AD).
